聚焦血肿瘤屏障——胶质母细胞瘤对血脑屏障影响的研究
研究建立由人诱导多能干细胞来源脑毛细血管内皮样细胞与U87-MG和U373-MG胶质母细胞瘤球体共培养的体外血肿瘤屏障测试系统,共培养仅24小时即出现紧密连接蛋白occludin和claudin-5表达降低及屏障完整性显著下降,跨内皮电阻从1313 ± 265 Ω*cm2降至712 ± 299 Ω*cm2(iBCECs + U87-MG)和762 ± 316 Ω*cm2(iBCECs + U373-MG),且3D球体较2D培养对标准化疗药更具耐药性。
要点
- 共培养24小时即见occludin和claudin-5表达降低及跨内皮电阻显著下降。
- 跨内皮电阻从1313 ± 265 Ω*cm2降至712 ± 299 Ω*cm2(iBCECs + U87-MG)和762 ± 316 Ω*cm2(iBCECs + U373-MG)。
- 3D球体在体外较2D培养对标准化胶质母细胞瘤化疗药更具耐药性。
核心结论
- 作者建立了简化的、稳健的体外血肿瘤屏障测试系统,可能应用于临床前治疗筛选及研究胶质母细胞瘤诱导的血脑屏障病理变化。
研究设计与样本
- 研究将人诱导多能干细胞来源的脑毛细血管内皮样细胞(iBCECs)与源自U87-MG和U373-MG细胞系的胶质母细胞瘤球体在细胞培养插入式格式中共培养。
- 球体监测培养168小时,并表征胶质母细胞瘤特异性标志物表达,用标准化疗药处理以区分2D单培养与3D球体的抑制效应。
主要发现
- 共培养仅24小时后iBCECs中紧密连接蛋白occludin和claudin-5表达降低,跨内皮电阻从1313 ± 265 Ω*cm2降至712 ± 299 Ω*cm2(iBCECs + U87-MG)和762 ± 316 Ω*cm2(iBCECs + U373-MG)。
- 3D球体在体外较2D培养对标准化胶质母细胞瘤化疗药更具耐药性。
- 研究还定量了胶质母细胞瘤诱导的血管内皮生长因子分泌。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) is the most prevalent, malignant, primary brain tumor in adults, characterized by limited treatment options, frequent relapse, and short survival after diagnosis. Until now, none of the existing therapy and treatment approaches have proven to be an effective cure. The availability of predictive human blood-tumor barrier (BTB) test systems that can mimic in-vivo pathophysiology of GBM would be of great interest in preclinical research. Here, we present the establishment of a new BTB in-vitro test system combining GBM spheroids and BBB models derived from human induced pluripotent stem cells (hiPSCs). METHODS: We co-cultured hiPSC-derived brain capillary endothelial-like cells (iBCECs) with GBM spheroids derived from U87-MG and U373-MG cell lines in a cell culture insert-based format. Spheroids were monitored over 168 hours (h) of culture, characterized for GBM-specific marker expression and treated with standard chemotherapeutics to distinguish inhibitory effects between 2D mono-culture and 3D spheroids. GBM-induced changes on iBCECs barrier integrity were verified via measurement of transendothelial electrical resistance (TEER), immunocytochemical staining of tight junction (TJ) proteins claudin-5 and occludin as well as the glucose transporter-1 (Glut-1). GBM-induced secretion of vascular endothelial growth factor (VEGF) was additionally quantified. RESULTS: Our hypothesis was validated by reduced expression of TJ proteins, occludin and claudin-5 together with significant barrier breakdown in iBCECs after only 24 h of co-culture, demonstrated by reduction in TEER from 1313 ± 265 Ω*cm2 to 712 ± 299 Ω*cm2 (iBCECs + U87-MG) and 762 ± 316 Ω*cm2 (iBCECs + U373-MG). Furthermore, 3D spheroids show more resistance to standard GBM chemotherapeutics in-vitro compared to 2D cultures. CONCLUSIONS: We demonstrate the establishment of a simplified, robust in-vitro BTB test system, with potential application in preclinical therapeutic screening and in studying GBM-induced pathological changes at the BBB.
引用
- Mathew-Schmitt S, Peindl M, Neundorf P, et al. Blood-tumor barrier in focus - investigation of glioblastoma-induced effects on the blood-brain barrier. J Neurooncol. 2024. PMID: 39196480. doi:10.1007/s11060-024-04760-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。